Forty years ago, researchers discovered one of cancer’s most elusive drivers. Today, oncology is beginning to learn what happens when that driver can finally be shut off.
Author: Corey Wise, Sr. Clinical Pharmacist
After nearly four decades of failed attempts to drug one of cancer’s most important oncogenes, the phase 3 RASolute-302 trial has demonstrated that broad inhibition of active RAS can double overall survival in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).[1]
The story is bigger than a positive clinical trial. It marks the culmination of one of oncology’s longest scientific pursuits and may fundamentally change how patients, providers, and payers think about RAS-driven cancers.
The RAS story began more than 40 years ago, when researchers identified mutations in the RAS family as fundamental drivers of human cancer. KRAS, NRAS, and HRAS quickly emerged as central regulators of cell growth, proliferation, and survival driving approximately 30% of all human cancers.[3] Yet biology repeatedly derailed drug discovery. RAS proteins lacked obvious binding pockets, exhibited exceptionally high affinity for GTP, and continually evaded conventional medicinal chemistry.[2-4]
The pharma industry’s first major strategy focused on farnesyltransferase inhibition. Despite some near successes with tipifarnib, this approach failed. Attention then shifted to downstream MAPK pathway inhibition, generating important therapies without ever directly shutting down RAS itself. For decades, “undruggable” became synonymous with one of oncology’s most important oncogenes.[2-4]
That perception changed in 2021 with the approval of sotorasib, a KRAS G12C inhibitor. Sotorasib and then adagrasib proved that RAS could indeed be targeted, ending one of oncology’s longest scientific droughts. But because these agents bind only the inactive GDP-bound form of a single KRAS mutation, their clinical reach is limited, and resistance commonly develops through reactivation of RAS signaling or downstream pathway activation.[2-5]
Could daraxonrasib represent the next chapter?
Rather than targeting one mutant allele, daraxonrasib is a first-in-class oral pan-RAS (RAS(ON) multiselective) tri-complex inhibitor that binds the active GTP-bound state of mutant and wild-type KRAS, NRAS, and HRAS. By forming a tri-complex with cyclophilin A, it sterically blocks RAS effector interactions and suppresses downstream MAPK signaling through a fundamentally different mechanism than earlier KRAS inhibitors.
For pancreatic cancer, that distinction is especially important. More than 90% of PDAC tumors harbor RAS mutations, most involving KRAS codon 12 substitutions. However, KRAS G12C mutations account for only approximately 2% to 3% of pancreatic cancers, leaving the majority of patients beyond the reach of first-generation KRAS inhibitors.[2] [4]
The Clinical Results Are Difficult to Ignore.
In RASolute-302, patients treated with daraxonrasib achieved a median overall survival of 13.2 months compared with 6.6 months for investigator’s choice chemotherapy (HR 0.40; P<0.001). Median progression-free survival improved from 3.5 to 7.3 months, while treatment-related discontinuation occurred in only 1.2% of patients versus 11.2% with chemotherapy.[1] Rash, diarrhea, stomatitis, and nausea reflected expected on-target biology but were generally manageable.
Importantly, RASolute-302 was powered on overall survival, the endpoint that matters most to patients, clinicians, and payers. At a time when many oncology approvals are supported primarily by surrogate endpoints such as progression-free survival or response rate, demonstrating a statistically significant improvement in overall survival with a hazard ratio of 0.40 provides an unusually strong evidence base for clinical adoption and future payer decision-making.[1]
For patients, those numbers are meaningful too. A treatment capable of doubling median overall survival and preserving quality of life begins to redefine expectations for metastatic PDAC, a disease where therapeutic advances have historically been limited.[1]
For Payers, the Story Extends Beyond Efficacy.
Daraxonrasib has the potential to treat an approximately 5x larger patient population than first generation KRAS-targeted therapies. If priced similarly to existing oral targeted oncology agents, per-patient economics may appear familiar. That said, aggregate budget impact almost certainly will not. Moving from a therapy applicable to a small molecular subset to one that could address more than 90% of patients with pancreatic cancer fundamentally changes the economics of precision oncology.[2] [4]
At the same time, acquisition cost alone will not determine value. Oral administration may reduce infusion-related healthcare resource utilization. Lower discontinuation rates may reduce treatment waste, while delaying disease progression could postpone subsequent therapies, hospitalizations, and supportive care. Formal cost-effectiveness analyses remain forthcoming, but the value discussion is already shifting from drug price to total cost of care.[1] [7]
The payer conversation therefore becomes less about whether to cover pan-RAS inhibition and more about how. Biomarker confirmation, indication-specific coverage and careful monitoring of real-world outcomes are likely to become central components of formulary strategy as additional evidence emerges.[1]
This additional data may ultimately prove even more transformative. Daraxonrasib is already being evaluated in phase 3 clinical trials in non-small cell lung cancer and colorectal cancer.[2] If those studies confirm the findings seen in pancreatic cancer, pan-RAS inhibition could evolve from a breakthrough therapy into a foundational oncology platform.
The next question is no longer whether RAS can be drugged. It is how quickly pan-RAS inhibition will move from pancreatic cancer into earlier lines of therapy, additional tumor types, and combination regimens—and whether payers can keep pace with what could become one of oncology’s largest new therapeutic classes. If RASolute-302 proves to be the first of several positive phase 3 studies, we may ultimately look back on this trial not as the end of the “undruggable RAS” story, but as the beginning of the pan-RAS era.
References
[1] O’Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. 2026.
[2] Wolpin BM, Park W, Garrido-Laguna I, et al. Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer. N Engl J Med. 2026.
[3] Ramesh S, Wang J, Huang CH, et al. Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance. Cancers. 2026.
[4] Der CJ, Yeh JJ. Advances in RAS Therapeutics for Pancreatic Cancer. N Engl J Med. 2026.
[5] Pilco-Janeta DF, De la Cruz-Puebla M. The Evolving Landscape of KRAS-Targeted Therapy: Mechanisms of Resistance and Emerging Strategies. Anti-Cancer Drugs. 2025.
[6] Garrido-Laguna I, Park W, Hong D, et al. Safety and Efficacy of Daraxonrasib Monotherapy as Later-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma. J Clin Oncol. 2026.
[7] Soto-Alsar J, Revuelta-Herrero JL, Villanueva-Bueno C, et al. Budget Impact Analysis of New Drugs in Oncology and Haematology: Principles and Practice. Br J Clin Pharmacol. 2025.